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Abstract. Endothelial function of vessels in patients with chronic kidney disease combined with subclinical 
hypothyroidism under the influence of combined antihypertensive therapy. Garmish I.P. The aim of the study: to 
evaluate the endothelial function of the vessels under the influence of combined antihypertensive therapy (valsartan 160 
mg / amlodipine 5 mg vs valsartan 160 mg / hydrochlorothiazide 12,5 mg) in patients with CKD and subclinical 
hypothyroidism. 80 patients with CKD I-II stages and AH 1 and 2 degrees were examined. According to TSH level 
patients were divided into 2 groups. Than patients with SH were separated into 2 subgroups: 1a – patients that received 
valsartan 160mg/ amlodipine 5 mg and 1b - patients that received valsartan 160mg/ hydrochlorothiazide 12,5 mg). 
More often violation of brachial artery flow-mediated dilation was found among the main group. The use of two-
component antihypertensive therapy based on valsartan 160 mg and amlodipine 5 mg or valsartan 160 mg and 
hydrochlorothiazide 12,5 mg ensured the achievement of target blood pressure levels in 83,3% and 84% of patients, 
respectively. The more significant improvement of brachial artery flow-mediated dilation was observed in patients that 
received fixed combination valsartan 160 mg/amlodipine 5 mg. 
 
Реферат. Ендотеліальна функція судин у хворих на хронічну хворобу нирок у поєднанні з субклінічним 
гіпотиреозом під впливом комбінованої антигіпертензивної терапії. Гарміш І.П. Мета дослідження: 
оцінити ендотеліальну функцію судин під впливом комбінованої антигіпертензивної терапії (валсартан 160 мг 
/ амлодипін 5 мг проти валсартану 160 мг / гідрохлортіазид 12,5 мг) у пацієнтів з ХХН і субклінічним 
гіпотиреозом. Досліджували 80 пацієнтів з ХХН I-II стадії та АГ 1 і 2 ступеня. Згідно з рівнем ТТГ пацієнти 
були розподілені на 2 групи. Потім пацієнти з субклінічним гіпотиреозом були розподілені на 2 підгрупи: 1a - 
пацієнти, які отримували валсартан 160 мг / амлодипін 5 мг та 1b - пацієнти, які отримували валсартан 
160 мг / гідрохлортіазид 12,5 мг. найчастіше порушення ендотелій-залежної вазодилятації було виявлено серед 
основної групи. Використання двокомпонентної антигіпертензивної терапії на основі валсартану 160 мг і 
амлодипіну 5 мг або валсартану 160 мг і гідрохлортіазиду 12,5 мг забезпечувало досягнення цільового рівня 
артеріального тиску у 83,3% і 84% пацієнтів відповідно. Більш значне поліпшення ендотелій-залежної 
вазодилятації спостерігалося в пацієнтів, які отримували фіксовану комбінацію валсартан 160 мг / амлодипін 5 мг.  
 
The relationship between elevated blood pressure 
(BP) and chronic kidney disease (CKD) is known 
for many years. On the one hand, CKD is the most 
common cause of symptomatic arterial hypertension, 
on the other hand, increased BP, despite its etiology, 
leads to a decrease in the functional capacity of the 
kidneys [1, 2]. Today, the frequency of arterial hy-
pertension (AH) among patients with CKD I-II sta-
ges is 40%, but with reduced glomerular filtration 
rate (GFR) up to 60 ml/min / 1,73 m2, this number is 
sharply increasing and at the terminal stage of CKD 
is over 90% [3]. It is well-known that mortality of 
nephrological patients is formed mainly due to 
cardiovascular events. Therefore, in modern 
medicine, the tactics of treating patients with CKD is 
based on: 1) the treatment of the kidney itself, if 
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possible; 2) reduction of cardiovascular risk, first of 
all it is the control of BP [4]. At the same time, 
today, more and more attention is paid to the states 
with a combination of two or more diseases. These 
conditions are called comorbidity (simultaneous da-
mage to two organs or body systems or two disea-
ses), poly-, multimorbidity (≥3 diseases), concomi-
tant pathology, or associated diseases. 
Thus, GFR decreasing is associated with a higher 
incidence of clinical and subclinical hypothyroidism 
(SH). SH is a proven lethality predictor among 
patients in dialysis, and a risk factor for nephropathy 
and cardiovascular events in patients with type 
2 diabetes [5, 6]. SH is also considered as a potential 
predictor of the development of complications and 
increased mortality in patients with CKD. Tradi-
tionally it is believed that with hypothyroidism, 
hypertension is noted with a predominant increase in 
diastolic blood pressure (DBP) [5, 7]. However, re-
cently there were results of researches, according to 
which the cause of hypertension in patients with 
hypothyroidism is heterogeneous: with an increase 
in the age of patients increases the percentage of 
patients with hypertension of mixed genesis, which 
leads to progressive increase in BP [8]. Thus, AH, 
CKD and SH contribute to the mutual aggravation of 
each of these diseases, the rapid development and 
progression of lesions of the target organs, and also 
substantially complicate the implementation of 
effective and safe antihypertensive therapy [3, 4]. 
ESH / ESC, taking into account the results of the 
ACCOMPLISH study, prefer the calcium channel 
blocker (CCB) as the second level of antihy-
pertensive therapy. In this study, the same ACE 
inhibitor was compared with a diuretic or calcium 
antagonist - the combination of ACE inhibitor diu-
retics was less effective in reducing of cardio-
vascular events than the combination of calcium 
antagonist, although BP in both groups did not 
differ. In the KDIGO recommendations 2012, pre-
ference is given to thiazide and thiazide-like diuresis 
(Clinical Practice Guideline for management of 
Blood Pressure in Chronic Kidney Disease). It 
should be noted that in existing studies where AH 
was studied in hypothyroidism, it was CCB that 
more effectively influenced on the BP level. Ho-
wever, a small number of studies on the charac-
teristics of the course and treatment of hypertension 
in patients with reduced function of the kidneys in 
combination with SH does not give an unambiguous 
answer, which combination of antihypertensive 
drugs will be more effective for these patients. 
The aim of the study: to evaluate the endothelial 
function of the vessels under the influence of 
combined antihypertensive therapy (valsartan 
160 mg / amlodipine 5 mg vs valsartan 160 mg / hy-
drochlorothiazide 12.5 mg) in patients with CKD 
and subclinical hypothyroidism. 
MATERIALS AND METHODS 
The study included 80 patients. The mean age of 
patients was 54.2±7.5 years, 49 men and 31 women. 
Criteria for inclusion: arterial hypertension 1-2th deg-
ree; CKD I-II stages (GFR>60 ml/min / 1.73 m2); 
presence of SH (TSH level>4.3 mE / l); signed in-
formed consent of the patient. The study was 
conducted in accordance with the requirements of 
the Helsinki Declaration and after approval of the 
local ethics commission of the medical institution. 
The diagnosis of SH was established after con-
sultation of the endocrinologist based on the levels 
of TSH and free T4. AH was diagnosed according to 
the Order of the Ministry of Health of Ukraine N 384 
of 24.05.2012 and recommendations ESH/ESC (2013) 
on treatment of hypertension. The diagnosis of CKD 
was established according to the Order of the Mi-
nistry of Health of Ukraine N 593 dated 12.12.2014. 
Exclusion criteria: GFR<60 ml/min /1.73 m2; TSH 
level >10 mU/l; type 1 diabetes and type 2 diabetes 
insulin-dependent; body mass index >40 kg/m2; 
hemodynamically significant cardiovascular disea-
ses, arrhythmias and heart disease requiring medical 
or surgical treatment, acute myocardial infarction 
and acute cerebrovascular accident in up to 6 months; 
resistant arterial hypertension; severe decompensated 
heart failure of the III-IV functional class. 
All patients were divided into 2 groups: the main 
group (n=55) – patients with CKD and subclinical 
hypothyroidism and the comparison group (n=25) – 
patients with preserved thyroid function and CKD. 
At the second stage, patients of the main group were 
divided into 2 subgroups, depending on the antihy-
pertensive therapy: 
• 1a subgroup (n=30) – patients with CKD in 
combination with SH who received a fixed com-
bination of valsartan 160 mg / amlodipine 5 mg 
• 1b subgroup (n=25) – Patients with CKD in 
combination with SH who received a fixed com-
bination of valsartan 160 mg / hydrochlorothiazide 
12.5 mg (Tab. 1). 
The office measurement of BP was performed 4 
times: at the beginning of the study, in 10 days, in 1 
month and 3 months. Brachial artery flow-mediated 
dilation was measured at the beginning of the study, 
and after 3 months. Investigation of the functional 
state of the endothelium by calculation of en-
dothelium dependent vasodilatation was carried out 
according to the method described by D. Celermajer 
[9]. With an increase in arterial diameter of 10% and 
above, the functional state of the endothelium was 
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considered to be preserved. The level of GFR was 
calculated using the formula CKD-EPI (2011) [9]. 
The statistical analysis was conducted using 
Microsoft Excel 2010 (Microsoft), STATISTICA for 
Windows 6.0 (StatSoft Inc., USA). The reliability of 
the differences was determined using Student's pa-
rametric t-criterion and Wilcoxon's non-pa-
rametric criterion. 
 
T a b l e  1  









18 (60%)/12 (40%) 15 (60%)/10 (40%) 16 (64%)/9(36%) 
Age, years (Ме [25%; 75%]) 55,21 [37; 65] 54,35 [36; 68] 54,79 [34; 67] 
Blood pressure (АТ), mm Hg 
Systolic (Ме [25%; 75%]) 160,1 [144; 180] 159,7 [143; 180] 153,4 [142; 179] 
Diastolic (Ме [25%; 75%]) 96,3 [86; 100] 95,9 [87; 112] 91,2 [85; 109] 
Heart rate per minute (Ме [25%; 75%]) 74,65 [64; 98] 72,42 [66; 95] 78,6 [71; 94] 
GFR, ml/min/1,73 m2 (Ме [25%; 75%]) 68,9 [64; 91] 71,1 [65; 92] 72,2 [69; 94] 
TSH level, mU/L (Ме [25%; 75%]) 7,29* [4,62; 9,26] 7,98* [4,54; 9,89] 2,18* [0,95; 3,86] 
N o t e .  * p<0,001 - the reliability of differences between groups. 
 
RESULTS AND DISCUSSION  
At the beginning of the study, a violation of the 
functional status of the endothelium of vessels was 
established among 52 (94,6%) patients with CKD in 
combination with subclinical hypothyroidism and 
among 18 (72%) patients  with  CKD  and  euthyroi- 
 
dism. In patients with CKD in combination with SH, 
inverse relationship was established between the 
level of TSH and the functional state of the vascular 
endothelium (r = -0,674; p <0,001) (Fig. 1). 
 
 
Fig. 1. Correlation between the level of TSH and the functional state  
of the endothelium of vessels in patients with CKD in combination with SH 
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Target BP levels after 3 months of observation 
were achieved in 25 (83.3%) patients of 1a subgroup 
and 21 (84%) patients of 1b subgroup. The doses of 
amlodipine up to 10 mg and hydrochlorothiazide 25 
mg per day, respectively, were increased for five 
patients of 1a subgroup and four patients of 1b 
subgroup that did not reach the target BP. Already in 
10 days a positive dynamic in the direction of 
lowering blood pressure in both subgroups was 
observed. But a statistically significant reduction of 
blood pressure was recorded only from the first 
month of combined antihypertensive therapy. At the 
end of the study, the systolic blood pressure (SBP) 
in 1a subgroup decreased by 22.9%, diastolic blood 
pressure (DBP) decreased by 14.5%; among patients 
of 1b subgroup SBP decreased by 18.2%, and DBP 
by 13.3% (p <0,01) (Fig. 2, 3). 
 
 
N o t e .  * p <0,01 - reliability of differences within subgroups 
Fig. 2. Dynamics of office SBP in patients with CKD  
and subclinical hypothyroidism during antihypertensive therapy 
 
 
N o t e .  * p <0,01 - reliability of differences within subgroups 
Fig. 3. Dynamics of office DBP in patients with CKD  
and subclinical hypothyroidism during antihypertensive therapy 
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In the beginning of the study violation of brachial 
artery flow-mediated dilation was detected in 27 
(90%) patients in the 1a subgroup and in 23 (92%) 
patients in 1b subgroup. A reliable improvement of 
the functional state of the endothelium was noted in 
both subgroups (Tab. 2). 
 
T a b l e  2  
Functional state of the endothelium of vessels of patients  
of both subgroups on the background of treatment 
1а subgroup (n=30)  1б subgroup (n=25) 
 
Before treatment After treatment p Before treatment After treatment p 
Patients with violation of  
brachial artery flow-mediated 
dilation, n (%) 
28 (93,3%) 6 (20%) <0,01 24 (96%) 8 (32%) <0,05 
Patients with normal violation 
of  brachial artery flow-
mediated dilation, n (%) 
2(6,7%) 24 (80%) <0,001 1 (4%) 17 (68%) <0,01 
 
However, a more pronounced increase in the 
diameter of the brachial artery was observed among 
the subgroup of patients receiving, a fixed com-
bination of valsartan 160 mg and amlodipine 5 mg 
as antihypertensive therapy. In this subgroup, the 
brachial artery flow-mediated dilation index increa-
sed by 2.8 times, and in the other subgroup – by 
2.1 times (Fig. 4). 
 
 
N o t e .  * p <0,05 - the reliability of the differences between subgroups. 
Fig. 4. Dynamics of the functional state of the endothelium in patients with CKD  
and subclinical hypothyroidism in the context of multi-component antihypertensive therapy 
 
CONCLUSIONS 
1. In patients with chronic kidney disease com-
bined with subclinical hypothyroidism, there is a 
more  pronounced  impairment  of   the  endothelial 
function of the blood vessels compared with those 
with thyroid preservation. 
2. The use of two-component antihypertensive 
therapy based on valsartan 160 mg and amlodipine 5 
mg or valsartan 160 mg and hydrochlorothiazide 
12,5 mg ensured the achievement of target blood 
pressure levels in 83.3% and 84% of patients, 
respectively. 
 5118/ Том XXIIІ / 3 ч. 1 
3. Two-component antihypertensive therapy 
based on valsartan 160 mg and amlodipine 5 mg 
significantly affects the functional state of the 
endothelium in patients with chronic kidney disease 
in combination with subclinical hypothyroidism 
compared with two-component antihypertensive 
therapy based on valsartan 160 mg and 
hydrochlorothiazide 12,5 mg. 
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